Physician profile

Michael Cohen

Cardiovascular Disease · Mobile, AL

NPI 1710938162

$1,346.38

in general payments reported to CMS, 2019-2025

16 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $206.97 2019-2020
Pfizer INC. $191.26 2019-2020
Sanofi-Aventis U.S. LLC $150.43 2019
Novartis Pharmaceuticals Corporation $147.10 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $137.51 2021
Akcea Therapeutics, INC. $123.07 2019
Amgen INC. $118.38 2019-2020
Janssen Pharmaceuticals, INC $59.45 2019-2020
Alnylam Pharmaceuticals INC. $46.49 2019
Novo Nordisk INC $35.50 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $31.22 2019
E.R. Squibb & Sons, L.L.C. $27.26 2019-2020
Gilead Sciences, INC. $24.55 2019
Medtronic Vascular, INC. $19.49 2019
Regeneron Healthcare Solutions, INC. $14.43 2019
Show all 16 companies
CompanyGeneral paymentsYearsTop products
Portola Pharmaceuticals, LLC $13.27 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Cohen

$1,346.38

in general payments reported 2019-2025

Years
2019-2021
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/260043/michael-cohen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.